Study S001646

A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06577090
Acronym: CBeyond
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 136
Start: 2024-08-22
Primary completion: 2026-11-20
Lead sponsor: Skye Bioscience, Inc.
Conditions: Obesity
Interventions: BIOLOGICAL:Nimacimab injection; BIOLOGICAL:Nimacimab placebo injection; COMBINATION_PRODUCT:semaglutide injection; BIOLOGICAL:Nimacimab 300 mg injection
Results posted: FALSE

Registered primary outcomes

Percent change in body weight (main study) [From Baseline to Week 26]
Nature, frequency and severity of AEs (study extension) [Baseline through Week 38 of study extension (approximately 10 months of participation)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.